Category Archives: Progesterone

Effects of Progesterone and 18-Methyl Levonorgestrel on Osteoblastic Cells

Abstract
Objective. To study the effects of progesterone (P) and 18-methyl levonorgestrel (LNG) on the expression of P receptors (PRA and PRB), c-fos, c-jun, and osteocalcin in the human osteosarcoma cell line MG-63 and human normal osteoblasts in order to understand the mechanism of progestin action on the proliferation and differentiation of osteoblasts. Methods. Cell proliferation was tested by MTT assay. The expression of PR, c-fos, c-jun, and osteocalcin was measured by semi-quantitative RT-PCR, Western immunoblot or immunocytochemistry. Results. Progesterone and LNG (10-10-10-6 M) stimulated cell proliferation in a dose-dependent manner. Continue reading

Progestin and Neuroprotection

Our understanding of the biology of gonadal steroids has expanded such that we now appreciate that the effects of gonadal steroid hormones, including estradiol and progesterone, extend beyond the strict confines of reproductive function and exert their effects on a wide range of tissue targets including, but not limited to, the bone, the heart and the brain. With respect to the brain, an increasing body of literature supports the protective effects of estradiol and progesterone. Continue reading

Effects of Progesterone and 18 on Osteoblastic

OBJECTIVE: To study the effects of progesterone (P) and 18-methyl levonorgestrel (LNG) on the expression of P receptors (PRA and PRB), c-fos, c-jun, and osteocalcin in the human osteosarcoma cell line MG-63 and human normal osteoblasts in order to understand the mechanism of progestin action on the proliferation and differentiation of osteoblasts. METHODS: Cell proliferation was tested by MTT assay. The expression of PR, c-fos, c-jun, and osteocalcin was measured by semi-quantitative RT-PCR, Western immunoblot or immunocytochemistry. RESULTS: Progesterone and LNG (10(-10)-10(-6)M) stimulated cell proliferation in a dose-dependent manner. Continue reading

Effect of Progesteorne vs Provera on Breast

Published online: 14 July 2006
Abstract The addition of the synthetic progestin medroxyprogesterone acetate (MPA) to postmenopausal estrogen therapy significantly increases breast cancer risk. Whether this adverse effect is specific to MPA or characteristic of all progestogens is not known. The goal of this study was to compare the effects of oral estradiol (E2) given with either MPA or micronized progesterone (P4) on risk biomarkers for breast cancer in a postmenopausal primate model. Continue reading

Progression of Atherosclosis in Menopausal Women not on Hormones

The Journal of Clinical Endocrinology & Metabolism Vol. 93, No. 1 131-138
Copyright © 2008 by The Endocrine Society
Relationship between Serum Levels of Sex Hormones and Progression of Subclinical Atherosclerosis in Postmenopausal Women
Roksana Karim, Howard N. Hodis, Frank Z. Stanczyk, Rogerio A. Lobo and Wendy J. Mack

Continue reading